LIXTE Biotechnology Announces Sarah Cannon Research Institute Joins City of Hope’s Ongoing Phase 1b Clinical Trial in Evaluating Lixte’s Lead Anti-Cancer Compound, LB-100, in Small Cell Lung Cance Apr 4, 2023 08:30AM
Lixte Biotechnology and City of Hope Enroll First Patient in Phase 1b Trial of Lead Compound LB-100 for Treatment of Small Cell Lung Cancer Jun 2, 2021 09:35AM
Lixte Biotechnology Holdings (LIXT), City of Hope Begin Phase 1b Clinical Trial of Lixte’s Lead Compound LB-100 to Treat SCLC Jan 19, 2021 09:44AM
Lixte Biotechnology and City of Hope to Initiate Phase 1b Clinical Trial of Lixte’s Lead Compound LB-100 to Treat Small Cell Lung Cancer Jan 19, 2021 09:35AM
Lixte Biotechnology and City of Hope to Initiate Phase 1b Clinical Trial of Lixte’s Lead Compound LB-100 to Treat Small Cell Lung Cancer Jan 19, 2021 09:35AM


Aug 21, 2018 09:47AM Lixte Biotechnology Holdings, Inc. (LIXT) Reports Clinical Trial Agreement with Moffitt Cancer Center to Initiate Phase 1b/2 Trial Evaluating the Safety & Efficacy of LB-100
Aug 21, 2018 09:45AM Lixte Biotechnology Announces a Clinical Trial Agreement with Moffitt Cancer Center to Initiate Phase 1b/2 Trial Evaluating the Safety and Efficacy of LB-100 in Treatment of Patients with Low or Inter